medicalnewstoday.com | Submitted by TeamADNA, 02.11.10
Clozapine, the antipsychotic agent used in the treatment of Schizophrenia has long been implicated as a trigger for Agranulocytosis in approximately two percent of patients treated with the drug. The SAEC, Serious Adverse Events Consortium, has announced a collaboration with Duke University to research genetic variants that could predict who is at risk for developing the often fatal disorder.